[HTML][HTML] Experimental Study of Almonertinib Crossing the Blood-Brain Barrier in EGFR-Mutant NSCLC Brain Metastasis and Spinal Cord Metastasis Models
Y Zhang, Y Zhang, W Niu, X Ge, F Huang… - Frontiers in …, 2021 - frontiersin.org
Roughly one third of non-small cell lung cancer (NSCLC) patients with epidermal growth
factor receptor tyrosine kinase inhibitor (EGFR-TKI)-sensitive mutated (EGFRm) tumors …
factor receptor tyrosine kinase inhibitor (EGFR-TKI)-sensitive mutated (EGFRm) tumors …
[HTML][HTML] Experimental study of EGFR-TKI aumolertinib combined with ionizing radiation in EGFR mutated NSCLC brain metastases tumor
Y Zhang, Y Li, Y Han, M Li, X Li, F Fan, H Liu… - European Journal of …, 2023 - Elsevier
Aumolertinib is an irreversible third-generation epidermal growth factor receptor tyrosine
kinase inhibitor (EGFR-TKI), although it has been administered for the treatment of …
kinase inhibitor (EGFR-TKI), although it has been administered for the treatment of …
[HTML][HTML] Potential benefit of osimertinib plus bevacizumab in leptomeningeal metastasis with EGFR mutant non-small-cell lung cancer
Y Yi, J Cai, P Xu, L Xiong, Z Lu, Z Zeng… - Journal of Translational …, 2022 - Springer
Background EGFR-mutant non-small cell lung cancer (NSCLC) is prone to leptomeningeal
metastasis (LM) after Tyrosine kinase inhibitors (TKIs) treatment. Our previous study …
metastasis (LM) after Tyrosine kinase inhibitors (TKIs) treatment. Our previous study …
Abstract CT190: A multicenter, open-label, single-arm, phase II study: The third generation EGFR tyrosine kinase inhibitor almonertinib for pretreated EGFR T790M …
S Lu, Q Wang, G Zhang, X Dong, CT Yang, Y Song… - Cancer Research, 2020 - AACR
Abstract Background: Almonertinib (HS-10296) is an oral, potent, high selective third
generation EGFR-tyrosine kinase inhibitor (EGFR-TKI) for sensitizing mutations and EGFR …
generation EGFR-tyrosine kinase inhibitor (EGFR-TKI) for sensitizing mutations and EGFR …
Preclinical comparison of osimertinib with other EGFR-TKIs in EGFR-mutant NSCLC brain metastases models, and early evidence of clinical brain metastases activity
Purpose: Approximately one-third of patients with non–small cell lung cancer (NSCLC)
harboring tumors with EGFR-tyrosine kinase inhibitor (TKI)-sensitizing mutations (EGFRm) …
harboring tumors with EGFR-tyrosine kinase inhibitor (TKI)-sensitizing mutations (EGFRm) …
[HTML][HTML] Intracranial efficacy and safety of furmonertinib 160 mg with or without anti-angiogenic agent in advanced NSCLC patients with BM/LM as salvage therapy
Z Xu, X Hao, Q Wang, K Yang, J Li, P Xing - BMC cancer, 2023 - Springer
Objectives Central nervous system (CNS) metastases including brain metastases (BM) and
leptomeningeal metastases (LM) are frequent in epidermal growth factor receptor (EGFR) …
leptomeningeal metastases (LM) are frequent in epidermal growth factor receptor (EGFR) …
Cerebrospinal fluid penetration rate and efficacy of afatinib in patients with EGFR mutation-positive non-small cell lung cancer with leptomeningeal carcinomatosis: a …
A Tamiya, M Tamiya, T Nishihara… - Anticancer …, 2017 - ar.iiarjournals.org
Background: Afatinib is an effective first-line treatment for epidermal growth factor receptor
(EGFR) mutation-positive advanced non-small cell lung cancer (NSCLC). However, few …
(EGFR) mutation-positive advanced non-small cell lung cancer (NSCLC). However, few …
[HTML][HTML] Efficacy of osimertinib for preventing leptomeningeal metastasis derived from advanced EGFR-mutated non-small cell lung cancer: a propensity-matched …
X Wang, J Cai, Z Zeng, A Liu - BMC cancer, 2021 - Springer
Background Leptomeningeal metastasis (LM) is a severe complication of advanced non-
small cell lung cancer (NSCLC). This retrospective study aimed to investigate the potential …
small cell lung cancer (NSCLC). This retrospective study aimed to investigate the potential …
Discovery of a Hydroxylamine-Based Brain-Penetrant EGFR Inhibitor for Metastatic Non-Small-Cell Lung Cancer
Metastases to the brain remain a significant problem in lung cancer, as treatment by most
small-molecule targeted therapies is severely limited by efflux transporters at the blood …
small-molecule targeted therapies is severely limited by efflux transporters at the blood …
[HTML][HTML] Restricting glutamine uptake enhances NSCLC sensitivity to third-generation EGFR-TKI almonertinib
Y Liu, X Ge, J Pang, Y Zhang, H Zhang, H Wu… - Frontiers in …, 2021 - frontiersin.org
The emergence of secondary resistance is the main failure cause of epidermal growth factor
receptor-tyrosine kinase inhibitors (EGFR-TKIs) as a targeted therapy for non-small cell lung …
receptor-tyrosine kinase inhibitors (EGFR-TKIs) as a targeted therapy for non-small cell lung …